CA2964808C - Methods and compositions using gdf15 polypeptides for increasing red blood cells - Google Patents

Methods and compositions using gdf15 polypeptides for increasing red blood cells Download PDF

Info

Publication number
CA2964808C
CA2964808C CA2964808A CA2964808A CA2964808C CA 2964808 C CA2964808 C CA 2964808C CA 2964808 A CA2964808 A CA 2964808A CA 2964808 A CA2964808 A CA 2964808A CA 2964808 C CA2964808 C CA 2964808C
Authority
CA
Canada
Prior art keywords
amino acid
gdf15
polypeptide
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2964808A
Other languages
English (en)
French (fr)
Other versions
CA2964808A1 (en
Inventor
Ravindra Kumar
Rajasekhar Naga Venkata Sai Suragani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA2964808A1 publication Critical patent/CA2964808A1/en
Application granted granted Critical
Publication of CA2964808C publication Critical patent/CA2964808C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2964808A 2014-10-30 2015-10-29 Methods and compositions using gdf15 polypeptides for increasing red blood cells Active CA2964808C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072889P 2014-10-30 2014-10-30
US62/072,889 2014-10-30
PCT/US2015/058116 WO2016069925A1 (en) 2014-10-30 2015-10-29 Methods and compositions using gdf15 polypeptides for increasing red blood cells

Publications (2)

Publication Number Publication Date
CA2964808A1 CA2964808A1 (en) 2016-05-06
CA2964808C true CA2964808C (en) 2023-06-27

Family

ID=55858354

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2964808A Active CA2964808C (en) 2014-10-30 2015-10-29 Methods and compositions using gdf15 polypeptides for increasing red blood cells

Country Status (6)

Country Link
US (2) US10603359B2 (cg-RX-API-DMAC7.html)
EP (2) EP3922259A1 (cg-RX-API-DMAC7.html)
JP (2) JP6663428B2 (cg-RX-API-DMAC7.html)
AU (2) AU2015339134B2 (cg-RX-API-DMAC7.html)
CA (1) CA2964808C (cg-RX-API-DMAC7.html)
WO (1) WO2016069925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3922259A1 (en) * 2014-10-30 2021-12-15 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
US11123430B2 (en) 2015-11-04 2021-09-21 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
US20190248852A1 (en) 2016-05-24 2019-08-15 Novo Nordisk A/S MIC-1 Compounds and Use Thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
KR20210065057A (ko) * 2019-11-26 2021-06-03 주식회사유한양행 지속형 gdf15 융합 단백질 및 이를 포함하는 약학 조성물
US12209112B2 (en) * 2022-09-15 2025-01-28 The Chinese University Of Hong Kong Methods of preventing or treating diseases, conditions, or disorders associated with chemotherapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4965251A (en) * 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
EP1105482A2 (en) 1998-08-21 2001-06-13 Princeton University Genes that regulate hematopoietic blood forming stem cells and uses thereof
AU2007334333B2 (en) 2006-12-18 2013-05-30 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for increasing red blood cell levels
WO2010019261A1 (en) 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010048670A1 (en) * 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease
CN105535938B (zh) 2009-08-13 2022-04-26 阿塞勒隆制药公司 Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
AU2012236700B2 (en) * 2011-03-29 2017-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of TMPRSS6 gene
AU2012340748A1 (en) 2011-11-22 2014-06-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN107459576A (zh) * 2011-12-14 2017-12-12 艾伯维德国有限责任两合公司 用于诊断和治疗铁相关病症的组合物和方法
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
EP2644278B1 (en) 2012-03-27 2014-12-10 Alfa Laval Corporate AB Centrifugal separator and method of controlling intermittent discharge
JP6758832B2 (ja) 2012-12-21 2020-09-30 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｇｄｆ１５抗体
EP2950807B1 (en) * 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) * 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
SG10201800800YA (en) * 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
JP2017509647A (ja) 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
WO2015196145A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
EP3922259A1 (en) * 2014-10-30 2021-12-15 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
TWI621976B (zh) 2015-07-24 2018-04-21 瑞鼎科技股份有限公司 內嵌式觸控面板驅動方法
AU2017228489A1 (en) * 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight

Also Published As

Publication number Publication date
JP2017533910A (ja) 2017-11-16
EP3212213B1 (en) 2021-04-28
AU2015339134A1 (en) 2017-04-27
US10603359B2 (en) 2020-03-31
JP7154241B2 (ja) 2022-10-17
AU2021232680A1 (en) 2021-10-07
US20200397863A1 (en) 2020-12-24
AU2015339134B2 (en) 2021-06-17
US11642394B2 (en) 2023-05-09
EP3212213A4 (en) 2018-05-30
CA2964808A1 (en) 2016-05-06
EP3922259A1 (en) 2021-12-15
JP6663428B2 (ja) 2020-03-11
WO2016069925A1 (en) 2016-05-06
US20180207236A1 (en) 2018-07-26
JP2020073603A (ja) 2020-05-14
EP3212213A1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
US11642394B2 (en) Methods and compositions using GDF15 polypeptides for increasing red blood cells
JP6796626B2 (ja) 無効赤血球生成を処置するための方法および組成物
JP5909446B2 (ja) 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用
JP2022009561A (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
US11807673B2 (en) Methods and compositions for increasing red blood cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015